Feigin, Andrew

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial

Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet

Deep Brain Stimulation and Movement DisordersVirus-based gene therapy research

Cited by 1,067

AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial

LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology

Deep Brain Stimulation and Movement DisordersParkinson's Disease Mechanisms and Treatments

Cited by 681

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG

Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology

Genetic Neurodegenerative DiseasesMetabolism and Genetic Disorders

Cited by 313

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

Feigin, A., Kaplitt, M. G., Tang, C., Lin, T., Mattis, P., Dhawan, V., During, M. J., & Eidelberg, D. (2007) · Proceedings of the National Academy of Sciences

Deep Brain Stimulation and Movement DisordersParkinson's Disease Mechanisms and Treatments

Cited by 181

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease

Niethammer, M., Tang, C. C., LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Sarkar, A., et al. (2017) · JCI Insight

Deep Brain Stimulation and Movement DisordersParkinson's Disease Mechanisms and Treatments

Cited by 124

Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study

Adams, J. L., Kangarloo, T., Tracey, B., O’Donnell, P., Volfson, D., Latzman, R. D., Zach, N., Alexander, R., Bergethon, P., Cosman, J., et al. (2023) · npj Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsContext-Aware Activity Recognition Systems

Cited by 98

Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine

Genetic Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments

Cited by 67

Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD: Human/Human trials: Other

Evans, E. E., Fisher, T. L., Leonard, J. E., Reader, A. M., Mishra, V., Mallow, C. L., Balch, L., Howell, A., Smith, E. S., Feigin, A., et al. (2020) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsGenetic Neurodegenerative Diseases

Cited by 7